Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laser therapy and Aflibercept for Diabetic Macular Oedema
NCT02432547Phase 4Completed
- Sponsor
- University of Sydney
- Start
- Jun 2017
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by University of Sydney. Started Jun 2017; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02432547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432547.